Navigation Links
InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
Date:5/29/2008

ment of ITMN-191 in combination with various antiviral compounds, including other small molecule direct antivirals, in both treatment-naive and treatment-experienced patients."

Phase 1b Triple Combination Trial Design

The Phase 1b placebo-controlled, triple combination study is anticipated to enroll up to approximately 50 treatment-nave patients chronically infected with HCV genotype 1. The study will assess the effects of multiple doses and regimens of ITMN-191 given in combination with pegylated interferon alpha-2a (Pegasys(R)) and ribavirin on safety, efficacy, pharmacokinetics and viral kinetics compared to the effects in patients treated only with pegylated interferon alpha-2a and ribavirin.

All patients will receive standard treatment with pegylated interferon alfa-2a and ribavirin. In addition to this standard treatment, patients will be randomized to receive either ITMN-191 or placebo, administered with a meal for a period of 14 days, and a single dose on Study Day 15.

Up to five cohorts of patients will be enrolled, exploring total daily doses starting at 300mg. Both twice daily and three-times-daily regimens will be studied to collect data on the safety, pharmacokinetic and viral kinetic effects of ITMN-191 when given with Pegasys and ribavirin.

InterMune expects to announce top-line results from the triple combination study during the fourth quarter of this year.

Publication Plans for ITMN-191

InterMune intends to submit several abstracts regarding ITMN-191 for possible presentation at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), scheduled for October 31 - November 4, 2008 in San Francisco. Among the abstracts submitted will be the clinical experience with ITMN-191 to date including, but not limited to, the results of the single-ascending-dose (SAD) study, the multiple-ascending-dose (MAD) monotherapy study of ITMN-191 as well as in-vitro results of ITMN-191 i
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
2. InterMune Announces Start of Phase 1b Trial of ITMN-191
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 IRIDEX Corporation (NASDAQ: IRIX ) ... 2015 financial results after the market closes on ... release, the Company will host a conference call with ... on Thursday, August 6, 2015 to ... developments. Interested parties may access the live ...
(Date:7/30/2015)... July 30, 2015  Tandem Diabetes Care®, Inc. ... and manufacturer of the t:slim® and t:flex™ Insulin ... non-exclusive Development Agreements with Dexcom, Inc. to allow ... with the Dexcom G5 and G6 continuous glucose ... generation pump platform with Dexcom,s future CGM systems ...
(Date:7/30/2015)... , July 30, 2015  Today we bring you a special edition of ... to remind you about some of our Medicare resources and continue highlighting the success ... Check out our latest infographics and videos here: ... ... ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
(Date:7/31/2015)... ... July 31, 2015 , ... Nutritional Products International, a company ... wellness products, announced the addition of Vincent Aquilino to its Board of Directors. ... and the prevention and rehabilitation of injuries, has spent the last 17-plus years ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... base, with the recent implementation of Microsoft Dynamics GP for a senior living ... Intellitec is now supporting senior living communities in 16 states. This further expansion ...
(Date:7/31/2015)... Orange, NJ (PRWEB) , ... July 31, 2015 ... ... obstructive sleep apnea (OSA) and the growing number of individuals who remain undiagnosed, ... of Americans continue to shy away from traditional CPAP therapy due to its ...
(Date:7/30/2015)... ... 31, 2015 , ... Reduce Human Error on the Drug ... and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice ... and device firms reduce manufacturing errors by 50 percent or more, will conduct ...
(Date:7/30/2015)... Dobbs Ferry, New York (PRWEB) , ... July 31, 2015 , ... ... President Barack Obama’s call to action by asking community members to contribute to the ... focused on, “Helping more of our young people stay on track. Providing the support ...
Breaking Medicine News(10 mins):Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3
... Comparative trials and observational studies previously conducted in ... These studies were performed before intracoronary stents and ... ,Therefore, Dr. Hanoch Hod, of Chaim Sheba ... followed 130 consecutive patients aged 70 or older ...
... vasectomy, contraception is typically left up to the woman. ... in a woman's contraceptive repertoire. Until now, men have ... searching for new options. Now, they may have one.// ... 12 percent. Vasectomies are considered permanent. Dr. Wang, of ...
... of choice for some doctors who think it's time to ... French physician invented it in the early 1800s. "The stethoscope ... allow you to distinguish between a heart that is beating ... ,"Sometimes the heart muscle is very weakened, but unless that ...
... spreads fast, and when it does, it can kill within months. ... tracks. ,Faith was more than a mere crutch for Rev. Jerry ... afraid of dying. My faith sustained me in that, but I ... highly curable if it's caught early, but it does not respond ...
... be found in water which has flowed through arsenic-rich ... drinking arsenic-rich water over long periods in countries world-wide. ... the earth's crust. ,Arsenic is introduced into water through ... groundwater //in some areas are elevated as a result ...
... affects women of child-bearing age, occurs when the the ... rendering them unable to produce eggs. PCOS symptoms include ... have said women// without these symptoms still can have ... though women's health experts caution that not every woman ...
Cached Medicine News:Health News:Angioplasty plus stenting better than thrombolysis for elderly patients with AMI, 2Health News:Arsenic in drinking water 2Health News:Arsenic in drinking water 3Health News:Arsenic in drinking water 4Health News:Arsenic in drinking water 5Health News:Arsenic in drinking water 6Health News:Arsenic in drinking water 7Health News:Arsenic in drinking water 8Health News:Polycystic Ovarian Syndrome(PCOS) linked to Diabetes 2
For use in cleaning soft contact lenses. Sensitive Eyes daily cleaner loosens and removes accumulations of film, deposits, and debris from soft contact lenses. Use with heat, chemical, and hydrogen p...
Complete Blink-N-Clean lens drops cleans and clears lenses in a blink. It is a unique blend of gentle to the eye ingredients that conveniently cleans, clears and keeps lenses feeling comfortable thro...
Renu rewetting drops soothe your eyes and moisturize soft contact lenses to minimize dryness....
Softwear Saline with unique comfort rinsing formula....
Medicine Products: